Abstract: The invention relates to dosage forms and formulations comprising the novel crystal modification A of the compound I-(2,6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide, wherein crystal modification A is characterized by characteristic lines with interplanar spacings (d values) of 10.5 ?, 5.14 ?, 4.84 ?, 4.55 ?, 4.34 ?, 4.07 ?, 3.51 ?, 3.48 ?, 3.25 ?, 3.19 ?, 3.15 ?, 3.07 ?, and 2.81 ?, determined by means of an X-ray powder pattern. Dosage forms of crystal modification A of the compound I-(2,6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide may be for oral or parenteral administration, in the form of a solid or liquid, and in a dosage range of 20 mg to less than 500 mg. Solid dosage forms comprise a tablet or capsule, and further comprise a pharmaceutically-acceptable carrier and film-coat.

Abstract: The invention relates to dosage forms and formulations comprising the novel crystal modification A of the compound I-(2, 6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide, wherein crystal modification A is characterized by characteristic lines with interplanar spacings (d values) of 10.5 ?, 5.14 ?, 4.84 ?, 4.55 ?, 4.34 ?, 4.07 ?, 3.51 ?, 3.48 ?, 3.25 ?, 3.19 ?, 3.15 ?, 3.07 ?, and 2.81 ?, determined by means of an X-ray powder pattern. Dosage forms of crystal modification A of the compound I-(2, 6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide may be for oral or parenteral administration, in the form of a solid or liquid, and in a dosage range of 20 mg to less than 500 mg. Solid dosage forms comprise a tablet or capsule, and further comprise a pharmaceutically-acceptable carrier and film-coat.

Abstract: The invention relates to the novel modifications B and C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula its use and pharmaceutical preparations comprising this crystal modifications.

Abstract: The present invention provides highly efficient methods for the preparation of {6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-1-phenyl-ethyl)-amine (I).

Abstract: The invention relates to the novel modifications B and C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula its use and pharmaceutical preparations comprising this crystal modifications.

Abstract: The invention relates to the novel modification A or A′ of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula 1

Abstract: The invention relates to the novel modification A or A′ of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula its use and pharmaceutical preparations comprising this crystal modification.

Abstract: The invention relates to the novel modification A or A′ of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula 1

Abstract: The invention relates to the novel modifications B and C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula their use and pharmaceutical preparations comprising this crystal modifications.

Abstract: The invention relates to the novel modifications B and C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula 1

Abstract: The invention relates to a novel process for producing 2-methoxybenzanthrones, starting with 1-aminoanthraquinones, which process is characterized in that, by application of a special reaction medium, namely a dimethylalkanephosphonate, which at the same time acts as a methylation agent in one of the reaction steps, the reaction is performed from beginning to end according to the principle of the single-vessel reaction, that is to say, without isolation of intermediates.The 2-methoxybenzanthrones obtained by this process are important intermediate products for vat dyes.